We report the outcome of 12 children who underwent unrelated cord blood transplant (U-CBT) in a single institution between February 1997 and July 1998. The 1 year event-free survival was 67% (95% CI of 26%). Four children died with infectious complication as cause of death in three cases. Immune reconstitution was studied during first year post transplant by assaying total lymphocyte counts, B cells, NK cells and T cell subsets in the eight disease-free surviving patients. We observed a prompt recovery of CD19 + cell number which was greater than 500/l at 9 months for all patients except the one with severe cGVHD. B cells constituted the predominant lymphocyte subset at 6 and 9 months post transplant with normal or elevated B cell numbers according to normal paediatric range. We noted normal serum immunoglobulin levels at 6 months post transplant for IgA and IgM and at 9 months for IgG. The CD3 + cell count and particularly the CD3 + CD8 + T cell subset remained depressed until 12 months post transplant. Six months after unrelated CBT, seven out of eight patients had less than 100 CD3 + CD8 + cells/l. CD3 + CD4 + cell recovery was less impaired with all children achieving an absolute count of CD3 + CD4 + cells greater than 200/l during the first year in a median of 5 months. The percentage of NK cells was elevated during the first 6 months after CBT but their absolute count remained within the normal range. Bone Marrow Transplantation (2000) 25, 53-57.
patients who underwent an unrelated CBT in our institution, eight had disease-free survival of more than 12 months after transplant and were analysed during the first year post transplant for immunological reconstitution.
Patients and methods

Patient characteristics
Twelve consecutive patients were transplanted with an unrelated cord blood in a single institution between February 1997 and July 1998. Median age at transplantation was 4.5 years (range 1.5-13.5) and median body weight 19 kg (range 11-36.5). Ten patients had an acute leukaemia (9 ALL, one AML). One patient with ALL failed to achieve remission within 28 days of induction therapy and was transplanted in first remission. Nine patients received unrelated CBT in second complete remission after relapse during therapy. One patient had juvenile CML and another a Kostmann's syndrome unresponsive to G-CSF therapy. Prior to transplant two patients were seropositive for cytomegalovirus (CMV), eight for Epstein-Barr virus (EBV) and four for toxoplasma.
Cord blood characteristics
HLA compatibility was assessed by HLA-A,B serological typing and DRB1 high resolution PCR-SSO typing. Five patients had a 5/6 HLA antigen match, five patients a 4/6 antigen match, and two a 3/6 mismatch. The median number of nucleated cells collected and infused was 4.8 ϫ 10 7 /kg (range: 2.9-11.7) and 3.5 ϫ 10 7 /kg (range: 2-11), respectively. Placental blood units were negative for CMV-specific IgM antibodies.
Pretransplant conditioning therapy
Eight patients received a 12 Gy fractionated total body irradiation (2 Gy twice daily for 3 consecutive days with lung shielding at 8 Gy) associated with cyclophosphamide (60 mg/kg/day for 2 days). Four received a combination of busulfan (480 mg/m 2 over 4 days) and cyclophosphamide (200 mg/kg) with addition of etoposide (30 mg/kg) in two cases.
Antithymocyte globulins (ATG: 2.5 mg/kg/day of Thy-moglobuline, Imtix-Sangstat, Lyon, France) were administered before transplant from day Ϫ3 to day Ϫ1.
Supportive care
Patients were hospitalised in laminar air flow rooms. Prevention of Pneumocystis carinii pneumonia included aerosolised pentamidine until the platelet count was greater than 100 000/l and cotrimoxazole thereafter. Fungal infection prophylaxis consisted of fluconazole during the first month and itraconazole until the third month. An immunoglobulin preparation was given at 500 mg/kg weekly until day 90 and every 2 or 3 weeks thereafter until 6 months after transplantation. The two recipients who were CMV positive received prophylactic treatment with foscarnet. Recombinant human granulocyte colony-stimulating factor was given post transplant to all patients.
Graft-versus-host disease (GVHD) prophylaxis
GVHD prophylaxis included cyclosporin A (CsA) and steroids in all cases. CsA was given for a total duration of 6 months (with full doses during the first 3 months). Steroid therapy was started at a dose of 3 mg/kg/day at day 5 after transplantation and gradually reduced to be withdrawn after 2 months. H-thymidine uptake. Serum Ig levels and IgG subclass were measured by nephelometry. Serum IgA and IgM levels were studied 6 months after CBT. IgG levels were measured at 9 months. Donor origin of reconstituted cells was documented by polymerase chain reaction (PCR) amplification of variable number of tandem repeat sequences. Genomic DNA was isolated from peripheral blood leukocytes using the salting out procedure precipitated with ethanol and resuspended in sterile water.
Evaluation of engraftment and immune recovery
8 D17S5, D16S83, D1S80 and APO B sequences were PCR amplified and detected after electrophoresis and ethidium bromide staining. Donor/recipient chimerism quantification was assessed by comparison with progressive dilutions of donor DNA into pretransplantation recipient DNA. The sensitivity of this method ranged between 1% and 2%.
Results
Survival and cause of death
According to the Kaplan-Meier method, the 1 year eventfree survival (EFS) was estimated at 67% (95% confidence interval 26%). Eight patients survived with a median follow-up duration of 15 months (range 12-25 months). However, one patient relapsed 20 months after transplant. Four patients died, one of early relapse and three of infectious causes.
Graft-versus-host disease (GVHD)
Acute GVHD was observed in six cases (grade I in four, grade II in two according to published classification 9 ). Of the nine patients surviving more than 100 days after transplant, two experienced chronic GVHD (one limited and one extensive). CsA and steroid therapy were stopped after a median of 6 and 4 months, respectively. All but one patient were free of immunosuppressive therapy at the last followup visit.
Engraftment
All except the patient who experienced an early relapse after transplantation were evaluated for neutrophil recovery. The median time to achieve an absolute neutrophil count (ANC) greater than 200/l and 500/l for 3 consecutive days was 22 days (range 10-93) and 28 days (range 11-100), respectively. Three patients died before platelet engraftment. For the nine remaining children, the median time to reach sustained platelet count of greater than 20 000/l and 50 000/l in the absence of platelet transfusion for 7 consecutive days was 66 days (range 17-128) and 82 days (range 20-129), respectively. Table 1 shows the chimerism data for 11 recipients studied during the first year post CBT. The patient who experienced an early post-transplant relapse was excluded from this analysis. All surviving patients had complete donor chimerism at the 12 month follow-up analysis. Of the 10 
Infectious complications
Of five patients who were positive for the herpes zoster virus before transplantation, four developed herpes zoster infections. Two were extensive and occurred during the first month after CBT. One patient had a CMV reactivation 2 months after CBT and was successfully treated with a combination of ganciclovir and foscarnet. Infectious complications were the cause of death in three children. One child had a fatal legionella infection with disseminated pulmonary, renal and hepatic micro-abcesses 2 months after transplant. The second, seropositive for toxoplasmosis before CBT, died from pulmonary toxoplasmosis during the second month post transplant and the third experienced an EBV cerebral lymphoma developed from donor cells, 7 months after transplant. The EBV genome was retrospectively studied in a sample of cryopreserved CB cells and was not detected.
Immune recovery
The changes in absolute values of total lymphocytes, T cell subsets, B cells and NK cells for the eight surviving recipients are shown at 3, 6, 9 and 12 months post transplant ( Table 2 ). The absolute count of total lymphocytes increased gradually during the first year post transplant to exceed 1500 cells/l at 9 months for seven out of eight patients. NK cells were within the normal range at each time point.
The absolute count of CD3 ϩ cells remained low in the first year post transplant. All the patients achieved an absolute count of CD3 ϩ cells greater than 500/l during the first year with a median time of 7 months (range 2-12 months).
CD3 ϩ CD8 ϩ cell numbers recovered slower than CD3 ϩ CD4 ϩ cell numbers. The CD3 ϩ CD8 ϩ subset was extremely low during the first 6 months post transplant. Seven out of eight children had an absolute CD3 ϩ CD8 ϩ cell count below 100/l at 6 months and less than 500/l at 9 months. Of note, the only patient who demonstrated prompt CD8 ϩ cell recovery had CMV reactivation 2 months after transplant.
The CD3 ϩ CD4 ϩ cell recovery was less impaired. All patients reached an absolute count of CD3 ϩ CD4 ϩ cells greater than 100/l at 6 months and six out of eight recipients had a CD3 ϩ CD4 ϩ cell count higher than 500/l at 9 months. For these eight patients, the median time duration to achieve 200 CD3 ϩ CD4 ϩ cells was 5 months (range 2- 
months). The percentage of CD45RA
ϩ in CD4 cells was determined at 1 year for all patients and ranged from 1% to 57% (median of 18%). The CD3 ϩ CD4 ϩ /CD3 ϩ CD8 ϩ ratio was higher than 1 at each time point during the first year after CBT for all patients except one. For seven patients CD19 ϩ B cell numbers increased rapidly after transplant with a median time to achieve an absolute count of B cells greater than 500 cells/l of 7 months (range 4-9 months). In contrast, the patient with extensive chronic GVHD had low B cell counts during the first year with CD19 ϩ cells remaining below 500 cells/l at the last follow-up (17 months).
The percentage of each lymphocyte subset during the first year post transplant is shown in Table 2 . The proportion of NK cells was predominant at 3 months and equal to the percentage of T lymphocytes at 6 months. CD3 ϩ and CD3 ϩ
CD8
ϩ cell percentages were low in the first year after CBT whereas the proportion of B cells was elevated, remaining higher than the T cell percentage until 9 months post transplant. CD19 ϩ cell reconstitution was accompanied by a normalisation of serum Ig levels. The median level of IgM and IgA at 6 months after CBT was 0.93 g/l (range 0.42-2.14) and 0.83 g/l (range 0.34-1.76), respectively. According to the recipient age-related range, the IgA level was higher than Ϫ2 standard deviation (s.d.) in seven out of eight patients at 6 and 9 months. 10 IgM level was greater than Ϫ2 s.d. for all children at the same time points.
At 9 months post transplant, the median IgG level was 12 g/l (range 6.6-19 g/l) and IgG level was greater than Ϫ2 s.d. for the seven patients free of immunoglobulin substi-tution. Two children presented an increase greater than ϩ2 s.d. in each immunoglobulin class.
Analysis of lgG subclass performed between months 8 and 12 showed values greater than the lower normal value for IgG1, 2 and 3. IgG4 was detectable in all cases with values ranging from 0.1 g/l to 0.32 g/l.
In vitro responses to PHA were performed at 9-12 months post transplant and were above the lower normal range (60 000 c.p.m.) in seven out of eight patients.
Discussion
Over recent years, CBT from unrelated donors has been used increasingly for paediatric patients who lack an HLA matched donor. The relative immaturity of cord blood lymphocytes gives rise to debate concerning their potential to induce GVHD and confer a graft-versus-leukaemia effect as well as to questions about the kinetics of immune reconstitution after CBT.
Several large clinical studies of unrelated CBT have reported low incidences of acute and chronic GVHD especially when compared with those observed after paediatric unmanipulated bone marrow transplantation from HLA matched or mismatched unrelated adult donors. [2] [3] [4] 11, 12 None of the children reported in our study experienced a grade III or IV acute GVHD.
Recently, Locatelli et al 4 reported the outcome of 102 children with acute leukaemia treated with related or unrelated CBT. The 2 year relapse estimates were 40% for the 60 patients transplanted from unrelated CB and 31% for those transplanted in first or second remission. In our report, where all the leukaemic children belong to a standard risk group for transplantation outcome, two relapsed, at 2 and 20 months post transplant. The observation documented by sequential chimerism analysis of an early autologous reconstitution followed by cord blood cell engraftment in a child suffering from JCML demonstrated that CB cells are capable of a potent allogeneic effect.
Few data are available on immune recovery after CBT. Previous CBT studies found that despite the low incidence of GVHD, infectious complications were a major cause of death after transplant. Infection contributed to 47% of deaths in Rubinstein et al's 3 report and for at least one third in Locatelli et al's 4 study. In our report, infection was responsible for death in three out of four cases.
Concerning reconstitution of lymphocyte populations after CBT, we found that B cells recovered early and at 6 and 9 months constituted the predominant lymphocyte subset. Absolute CD19 ϩ cell numbers were elevated at 12 months for all patients except the one with severe chronic GVHD. Nonetheless, B cell values often remained in the upper normal range for healthy control matched for age. 13 Locatelli et al 5 previously described three patients after related CBT. They reported an impressive increase in the number and the percentage of B cells with CD19 ϩ cell counts above 1000/l as early as 4 months post transplant. This finding was subsequently confirmed by Moretta et al 7 in a preliminary report concerning 12 children who received either related or unrelated CBT. Probably to a lesser extent, B lymphocyte numbers exceeding normal levels are also noted in recipients of matched sibling donor (MSD) transplants. [14] [15] [16] In our study, serum IgA, M and G levels rapidly normalised, reaching for all patients except one the normal range for recipients' age at 6, 6, and 9 months respectively. After MSD-BMT patients have normal IgM production after 4-6 months and normal IgG production by 7-9 months. 17 In our report, T cell lymphopenia was observed in the first year following CBT. CD3 ϩ and in particular CD3 ϩ CD8 ϩ cell subset recovery was slower than after MSD-BMT. Near normal CD3 ϩ cell numbers were observed between 6 and 12 months post MSD-BMT and CD8 ϩ cell numbers, which are generally in the normal range as early as 3 months post transplant, regenerate more rapidly than the CD4 ϩ cell population. 13, [18] [19] [20] Of note in our report, the CD3 ϩ CD8 ϩ lymphocyte population was defined using two-colour staining which excluded NK cell contamination. In Locatelli's report, patients received CsA alone for GVHD prophylaxis and demonstrated a prompt T cell recovery after HLA-identical related CBT. Their CD3 ϩ cell counts were greater than 1000/l at 6 months with an inverted CD4/CD8 ratio. The low T cell values observed in our report were more comparable to those noted by Kook et al 21 who studied immune reconstitution in 102 children receiving T lymphocyte-depleted bone marrow from either partially matched familial donor or from matched unrelated donor. The authors reported that CD3 ϩ cell numbers did not normalise until 2 to 3 years post transplant, but this prolonged depression concerned mainly CD4 cells and the B cell subset also remained depressed during at least the first year post transplant. In the setting of HLA mismatched transplant, immunosuppressive therapy administered during BMT and particularly the use of antithymocyte globulins can further impede T cell function by mediating an in vivo T cell depletion. Finally, immaturity of cord blood lymphocytes as well as the low number of T cells infused could also partly explain the lack of early mature donor-derived CD8 ϩ lymphocyte expansion after CBT. [22] [23] [24] [25] [26] [27] The second step of immunological recovery after transplant is generated by the differentiation of donor hematopoietic stem cells with recipient age playing a central role in thymic CD4 ϩ cell regeneration. [28] [29] [30] In our study, although CD4 ϩ cell numbers did not normalise at 1 year, all children reached a 200 CD4 ϩ cell count between 2 and 11 months post transplant. We observed CD4
ϩ cell values greater than those noted after paediatric partially matched T celldepleted BMT, where higher doses of ATG were used. 21 The proportion of naive CD4 ϩ cells (CD45RA ϩ cells in CD4) at 12 months was extremely variable and below 5% for three patients. The role of age, GVHD and its treatment could not be assessed because of the small sample size.
To summarise, after CBT, the CD3 ϩ CD8 ϩ cell subset was particularly depressed during the first 6 months whereas the CD4 ϩ cell population reconstituted gradually. Recovery of NK cells was prompt. CD19 ϩ cells were normal or elevated as early as 6-9 months with simultaneous normalisation of serum immunoglobulin levels. Because we studied only eight patients, further larger studies are warranted to confirm this pattern of immune reconstitution and to investigate the possible relationship between GVHD, clinical infections and immune recovery after unrelated CBT.
